First antibody reagents pre-tested and optimised for cytometry...

Guava Technologies, Inc., a leading developer of cost-effective and accessible cell-analysis systems for life science research, drug discovery, development and clinical diagnostics, has announced the introduction of Express Cell Surface Antibodies, a new line of antibody reagents designed to identify subsets of hematopoetic-derived cells by their patterns of protein expression.

This is the first of several new reagent lines that Guava intends to introduce this year for use by life sciences researchers.

Guava's new Express Cell Surface Antibody reagents allow researchers to examine a very specific population of hematopoetic-derived (blood) cell lines for their functional responses to compounds or other treatments. These antibodies have been conveniently optimised for ease of use with the Guava EasyCyte™ and EasyCyte™ Mini systems.

With the introduction of Guava's new Express Cell Surface Antibodies, researchers will have the convenience of the first antibody reagents specifically pre-tested and pre-optimised for use with cytometry systems. The new reagents allow researchers to analyse the functional responses of one cell type in a mixed population of cells, such as whole blood. Importantly, the new reagents are ideal for automated sampling in 96-well plates, saving time and reducing sample size.

Guava's Express Cell Surface Antibodies are a line of monoclonal antibodies specific for proteins on human hematopoetic-derived blood cells. Guava's antibodies are offered as direct conjugates to one of three different fluorescent dyes, eliminating the need for secondary staining and wash steps in the staining protocol. Developed for use with Guava's microcapillary cytometry systems, the new antibodies are available in concentrations that eliminate extra dilution steps associated with other antibodies. Guava's Express Cell Surface Antibody reagents, and its entire line of assays and systems, are further described on the company's website at:
www.guavatechnologies.com/main/products/expressantibodies.cfm.

Larry Bruder, Guava Technologies' chief executive officer, stated, "Guava has developed the most sophisticated and robust bench top systems and assays for the drug discovery and cell biology communities. This year, we are introducing a number of new reagent lines that can allow greater scalability and efficiency of sampling, thereby reducing costs. These reagents reflect Guava's ongoing commitment to revolutionising the way that a variety of cell-based assays are performed."